Form 4: Syndax Pharmaceuticals Executive Stock Sale

Head of R&D and CMO Nicholas A.J. Botwood exercised options and sold 65,515 shares of Syndax Pharmaceuticals common stock.

Summary

• Nicholas A.J. Botwood, Head of R&D and CMO, exercised options to acquire 53,750 shares of Syndax Pharmaceuticals (SNDX) at a strike price of $13.82.
• Following the exercise, the executive sold a total of 65,515 shares across two days (June 11 and June 12, 2026).
• The sales were executed at weighted-average prices of $18.00 and $18.14 per share.
• The transactions were conducted pursuant to a pre-established Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be perceived negatively, the use of a 10b5-1 plan suggests routine financial planning rather than a lack of confidence in the company.

Positives

• The executive maintains a remaining balance of 60,885 shares of common stock.
• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-planned divestment rather than a reactive market move.

Negatives

• The executive reduced their direct beneficial ownership of common stock through the sale of 65,515 shares.

Risks

• Continued selling by key insiders may signal to the market that management believes the stock is near its near-term valuation peak.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a disclosure of insider transaction activity.

Management Comments

• The transactions were executed in accordance with a Rule 10b5-1 trading plan.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for biotech executives to manage personal liquidity and diversify holdings, often occurring after significant stock price appreciation.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to avoid allegations of insider trading.
• The volume of shares sold is consistent with typical executive equity compensation liquidation patterns in the mid-cap pharmaceutical sector.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though it remains within the context of a pre-planned trading arrangement.

Next Steps

• Monitor future Form 4 filings for additional insider activity.

Key Dates

Keywords

Syndax Pharmaceuticals, SNDX, Insider Trading, Form 4, Biotech, Executive Compensation